2006 Industry Dynamics: Lessons to Be LearnedDecision ResourcesDecember 21, 2006 35 Pages - SKU: DECR1402582 |
|
China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medi
5/20/2013 | published by: Access China Management Consulting Ltd.
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of traditional Chinese medicines almost can not been expressed by
|
read more...
|
$750.00
|
|
Global Medication Management System Market 2012-2016
5/3/2013 | published by: Infiniti Research Limited
Global Medication Management System Market 2012-2016 TechNavio's analysts forecast the Global Medication Management System market to grow at a CAGR of 5.42 percent over the period 2012-2016. One of the key factors contributing to this market
|
read more...
|
$2,000.00
|
|
Cote d'Ivoire Pharmaceuticals and Healthcare Report Q3 2013
5/15/2013 | published by: Business Monitor International
BMI View: The risks of investing in Côte d'Ivoire's pharmaceutical and healthcare industry arenumerous. Politically, the country is in a fragile state, with concerns over security commonplace.Economically, Côte d'Ivoire posts a better performance, but there
|
read more...
|
$1,295.00
|
|
Croatia Pharmaceuticals and Healthcare Report Q3 2013
5/15/2013 | published by: Business Monitor International
Executive Summary BMI View: Croatia's entrance into the EU will accelerate its economic liberalisation and the developmentof the country's private sector. It is also likely to bring about an influx of EU funding in modernising thecountry's
|
read more...
|
$1,295.00
|
|
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q3 2013
5/15/2013 | published by: Business Monitor International
BMI View: Sudan will remain one of the least attractive countries in the Middle East/Africa region due tolow pharmaceutical and healthcare expenditure. The government's low commitment to healthcare,combined with political and economic uncertainties, will remain
|
read more...
|
$1,295.00
|
|
Algeria Pharmaceuticals and Healthcare Report Q3 2013
5/22/2013 | published by: Business Monitor International
BMI View: Algerian authorities appear committed to healthcare development programme, the 2010-2014tranche of which envisages the construction of more than 150 new hospitals and numerous otherfacilities. This expansion of medical services will provide an impetus
|
read more...
|
$1,295.00
|
|
Taiwan Pharmaceuticals and Healthcare Report Q3 2013
5/22/2013 | published by: Business Monitor International
BMI View: Taiwan will continue to represent a modestly attractive proposition for drug manufactures. Ourview is based on factors such as the maturity of its pharmaceutical market, government encouragement ofgeneric medicines and authorities desire to
|
read more...
|
$1,295.00
|
|
Zambia Pharmaceuticals and Healthcare Report Q3 2013
5/22/2013 | published by: Business Monitor International
BMI View: Zambia has a strong economy thanks to its relative political stability and copper miningindustry, but there are considerable gaps in its provision of healthcare services. With many specialisthealthcare professionals concentrated in the capital,
|
read more...
|
$1,295.00
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2013
5/8/2013 | published by: Business Monitor International
BMI View: While the patent cliff and the consequent availability of generic drugs, as well as price cuts ongeneric medicines and their increasing affordability, will work towards increasing the consumption ofgeneric medicines in Switzerland, BMI
|
read more...
|
$1,175.00
|
|
Australia Pharmaceuticals and Healthcare Report Q3 2013
5/8/2013 | published by: Business Monitor International
BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceuticalinvestors, given its ageing and generally affluent population. Importantly, the government is implementingcost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers
|
read more...
|
$1,175.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Prescription Drugs Reports